ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Kidney Patients at High Immunological Risk Can Be Safely Transplanted With a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab

D. Halleran,1 J. Melancon,2 V. Whittaker.1

1Surgery, State University New York Upstate Medical University, Syracuse, NY
2Surgery, George Washington University, Washington, DC.

Meeting: 2015 American Transplant Congress

Abstract number: A146

Keywords: Induction therapy, Kidney transplantation, Panel reactive antibodies, Retransplantation

Session Information

Date: Saturday, May 2, 2015

Session Name: Poster Session A: Kidney Immunosuppression: Induction Therapy

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Exhibit Hall E

Related Abstracts
  • Preliminary Results of a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab in a Pediatric Patient Population Undergoing Kidney Transplantation
  • Ideal Versus Total Body Weight Dosing of Rabbit Anti-Thymocyte Globulin Induction Therapy on Patient Outcomes in High Immunological Risk Kidney Transplant

Purpose: We report the outcomes from our single center experience with the novel induction regimen using rATG (3 mg/kg) in divided doses given on operative day zero and post-operative day one and basiliximab (20 mg) given on day two, followed by steroid-free maintenance therapy for patients with high immunological risk undergoing kidney transplantation.

Methods: We retrospectively reviewed 208 consecutive patients who underwent kidney transplantation from 1/1/2009 to 9/1/2014 at our institution. Patients were identified as high immunological risk if their peak PRA was ≥ 20 or if they underwent previous transplantation. 21 patients were identified in the current rATG plus basiliximab group, and 48 in the historical basiliximab with steroid taper group. Outcomes between the two groups were compared using hospital length of stay, biopsy proven rejection episodes, infectious complications, graft failure, and death, for a period of up to 1 year.

Results: The mean peak PRA in the two groups was 62.6% and 66.6%, respectively. The length of stay patients receiving the current regimen was 4.1 days compared to the historical cohort average of 7.1 days. Readmission rates in the two groups were comparable at 42.8% (9/21) and 54.1% (26/48), respectively. Infectious complications were comparable at a rate of 47.6% (10/21) and 45.8% (22/48) between the two groups. Graft failure occurred in 0% (0/21) and 12.5% (4/48) between the two groups, and death in 0% (0/21) and 2.1% (1/48). Of particular interest, there was a difference in rejection events between the two groups, at 4.8% (1/21) and 12.5% (6/48).

Conclusions: In patients at high immunological risk for rejection, our preliminary data suggests that a regimen of rATG plus basiliximab can be safely used for induction in kidney transplantation.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Halleran D, Melancon J, Whittaker V. Kidney Patients at High Immunological Risk Can Be Safely Transplanted With a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/kidney-patients-at-high-immunological-risk-can-be-safely-transplanted-with-a-novel-induction-regimen-using-anti-thymocyte-globulin-rabbit-ratg-plus-basiliximab/. Accessed February 25, 2021.

« Back to 2015 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Left-Sided Donor Nephrectomy Predisposes Living Kidney Donors to Latent Adrenal Insufficiency with Symptoms of Fatigue and Inferior Quality of Life.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.